Tel Aviv University

Kadmon Corporation, LLC

Novelix Pharmaceuticals, Inc.

Concordia Pharmaceuticals, Inc.

Victor J Bauer

Yoel Kloog

Burkhard Jansen

Mike H O'Neill

Liat Goldberg

Barbara J Kidon

Disclosed are alkoxyalkyl S-prenylthiosalicylates and pharmaceutical compositions containing the same and a pharmaceutically acceptable carrier. Methods for treating a human afflicted with cancer, including solid tumors, or a hematological malignancy by administering to the human in need thereof an effective amount of an alkoxyalkyl S-prenylthiosalicylate are also disclosed.

Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer

Disclosed are oral dosage forms containing a Ras antagonist including FTS and structural analogs thereof, and at least one pharmaceutically acceptable excipient other than a cyclodextrin, and methods of orally administering same to treat diseases and disorders responsive to the Ras antagonists.

Methods and compositions for oral delivery of FTS

A novel co-crystal of N'-(7-fluoropyrrolo[1,2a]quinoxalin-4-yl)pyrazine-2-carbohydrazide with oxalic acid is disclosed. The disclosed oxalic acid co-crystal demonstrates cancer cell growth inhibition and is more bioavailable than the corresponding free base when administered as a suspension.

(Pyrroloquinoxalinyl) pyrazinecarbohydrazide-oxalic acid co-crystal for treatment of cancer and other diseases

Growing community of inventors

Bridgewater, NJ, United States of America

Victor J Bauer